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Introduction 
 Since their discovery stem cells have had enormous potential in the medical 
field, but the surrounding controversy has hindered progress. Stem cells are sought 
after for their ability to develop into various cell types, replenish other cells, and 
work as an “internal repair system.”1 The value of these cells lies in their ability to 
continuously divide, or under specialized conditions, their ability to form different 
body tissues/organs.2 Typically, research has been geared towards two types of 
stem cells. The first is known as Embryonic Stem Cells, which are derived from the 
inner cell mass of embryos and cultured through in vitro fertilization.3 The second 
type, which will be the primary focus of this paper, are known as Adult or non-
embryonic Stem Cells. Similar to their embryonic counter parts, adult stem cells can 
                                                        
1 National Institutes of Health, U.S. Department of Health and Human Services, Stem 
Cell Basics: Introduction, available at 
http://stemcells.nih.gov/info/basics/pages/basics1.aspx (last visited April 16, 
2013). 
2 Id. 
3 THE PRESIDENT’S COUNCIL ON BIOETHICS, MONITORING STEM CELL RESEARCH: A REPORT OF 
THE PRESIDENT’S COUNCIL ON BIOETHICS , pg. 8 (Pre-Publication Version Washington, 
D.C.: January 2004). 
be cultivated to form various lineages of specialized cells,4 but are derived from a 
living human rather than an embryo.  Although these adult cells are partially 
differentiated, they are believed to have a similar ability to form varying cell types. 
Nonetheless, ethical, moral, and social implications have limited the progress of 
research, and the development of cutting edge therapies with the potential to 
cure/mitigate a wide array of medical aliments.  
 In today’s day and age, innovation and technology are at the forefront of our 
healthcare revolution. Modern medicine continues to evolve as researchers discover 
cures and treatments to a wide array of medical conditions. While scientists agree 
stem cells are full of potential, a lack of research and funding has limited the 
availability of treatments and therapies stemming from these “miracle cells.”5 Stem 
cells are highly desired by virtue of the fact that they are unspecialized.6 Similar to a 
ball of clay, when certain conditions are met, these cells can be manipulated to form 
almost anything. Known as regenerative medicine, treatments involving use of these 
cells appear to be limitless on their face, but the use of cell therapy remains at an 
experimental stage, with no concrete proof as to the safety and efficacy and such 
treatments.7 
 This hesitation has led individuals to seek treatment elsewhere, often times 
traveling outside of the United States to dodge strict FDA regulation of these 
treatments. Most notably, this phenomenon can be traced to various professional 
                                                        
4 Id. at 10. 
5 Id. 
6 See Stem Cell Basics:Intro, supra note 1. 
7 International Society for Stem Cell Research, Frequently Asked Questions: 
Understanding Stem Cells, available at http://www.isscr.org/home/resources/learn-about-
stem-cells/stem-cell-faq (last visited April 18, 2013). 
athletes who can afford the travel and costs of adult stem-cell therapy. This paper is 
designed to address this behavior, and compare the United States to other 
prominent countries more advanced in this field. While the future is full of 
possibilities, starting the race behind could make it difficult for the United States to 
catch up. Should this procedure remain outside the scope of FDA regulation? Or 
should the United States eagerly adopt these “unproven” practices in hopes of future 
success? 
I. A Brief Overview of Stem Cell Regulation 
A. Embryonic Stem Cell Research 
Most of the controversy surrounds the use of embryonic stem cells. As 
mentioned above, these cells are the by products of in vitro fertilization. The 
government must balance the interest of this potential life, against the potential 
good that can result from the “destruction” of said embryos. Around the time of 
their discovery, Congress recognized an ethical battle surrounded the use of these 
cells. In 1996, Congress adopted what is known as the “Dickey Amendment,” 
prohibiting federal funding for research that destroys or seriously endangers human 
embryos, or creates them for research purposes.8 The amendment made no mention 
of using these techniques when private funding is involved.9 This has been a cause 
for controversy and led to various interpretations of the amendment. On one hand, 
the destruction of these embryos seems inherently wrong. On the other, the 
amendment does not prohibit what can or cannot be done, simply what actions are 
worthy of federal funding. Ever since its enactment, the Clinton and Bush 
                                                        
8 OMNIBUS APPROPRIATIONS ACT, PL 111-8, March 11, 2009, 123 Stat 524 (2009). 
9 Id. 
administrations have addressed the Dickey Amendment in hopes of clearing up the 
water. In reality, until recently the ban was left largely unchanged.  
On March 9, 2009 President Obama issued Executive Order 13505,10 
“Removing Barriers to Responsible Scientific Research Involving Human Stem Cells,” 
which attempted to expand the scope of embryonic stem cell research. The purpose 
of the order was to lift the earlier perceived limitations of the Bush administration 
and enhance the support of the Nation Institute of Health, (“NIH”), for research 
involving human stem cells.11 Following this executive order, the NIH released new 
guidelines for federal funding surrounding stem cells. Human Embryonic Stem Cells 
can now be donated for research so long as certain conditions are met.12 The stem 
cells must be created via in vitro fertilization, donated through voluntary written 
consent to be used for research, with no funding or coercion, accompanied by 
informed consent.13Although these embryonic stem cells are thought to have more 
potential, they come with more barriers. While the limitations on research are 
gradually broadened, we are still years away from proven therapy. It will take time 
to test, develop, and implement an approved treatment using these embryonic cells. 
Although this is a step in the right direction, the fact of the matter is these 
embryonic cells remain highly controversial. The main focus of this paper will 
revolve around the use and development of treatments and therapies surrounding 
                                                        
10 Removing Barriers to Responsible Scientific Research Involving Human Stem 
Cells, 74 FR 10667, Exec. Order No. 13505 (2009). 
11 Id.. 
12 Id. 
13 See Stem Cell Basics:Intro, supra note 1. 
the less controversial, adult, non-embryonic stem cells, specifically what is known as 
Regenokine therapy.  
B. Adult Stem Cell Research 
Adult stem cells are themselves are undifferentiated, although they are found 
within cells that have already differentiated into a particular type of tissue.14 They 
are slightly more limited in their ability to develop into cell types and tissues 
different from the original from which they were derived.15 Most commonly, these 
cells are used to restore and repair dying tissue within the body.16 Since these cells 
are usually taken and later re-injected into the same individual, they are less 
controversial than the Embryonic Stem Cells, due to their autologous use. Given 
their ability to regenerate and self-renew, these adult stem cells have sparked much 
interest within the medical research community. Their cultivation does not involve 
the destruction of any embryos, nor does it raise the same ethical concerns as are 
present with the embryonic counterparts. The cells are drawn from the individual 
adult patient, and later put back into the same individual. If one decides to accept 
the risks, they should be able to reap the rewards, however the FDA takes a very 
different position. The FDA considers treatments involving these adult stem cells to 
be drugs within the scope of regulation, rather than medical practices, which they 
have no control over. This has led to controversy between those physicians willing 
to adopt these advanced medical procedures, and the governing body of the FDA. 
                                                        
14 See Stem Cell Basics:Intro, supra note 1. 
15 National Institutes of Health, U.S. Department of Health and Human Services, Stem 
Cell Basics: What Are Adult Stem Cells, available at 
http://stemcells.nih.gov/info/basics/pages/basics4.aspx (last visited April 16, 
2013). 
16 Id.  
II. Adult Stem Cells and Regenokine Therapy 
In recent years, adult stem cell research has been put into practice as 
physicians have begun to treat patients using their own adult stem cells. While the 
treatment gains support among the medical community, recent litigation and 
legislation concerning FDA regulation has halted these practices in the United 
States. 
A. Regenokine Method 
Known as Regenokine therapy, this treatment was discovered and developed 
in Dusseldorf, Germany by Dr. Peter Wehling, a spinal surgeon.17It involves a 
process of removing an individual’s own adult stem cells, and later reintroducing 
said cells back into the body, for an “anti-inflammatory” effect.18 The procedure 
begins with a physician drawing approximately two ounces of blood from the 
individual.19 The blood is then incubated and kept at a slightly elevated 
temperature, essentially exposing the cells to a fever.20 Next, the blood is placed in a 
centrifuge, where the various genetic materials begin to separate.21 Sometimes 
additional nutrients are added to the serum, or the serum is drawn and then directly 
injected back into the patient22. The treatment typically, lasts about five days and 
                                                        
17 See Nat’l Inst. Of Health, Stem Cell Basics: What Are Adult Stem Cells? supra note 
15. 
18 Id. 
19 Singularity Hub, Regenokine: The Unproven Treatment That Professional Athletes Are 
Flying to Germany For, available at http://singularityhub.com/2012/04/24/regenokine-
the-unproven-treatment-that-professional-athletes-are-flying-to-germany-for/ (last visited 
Apr. 27, 2013).   
20 Id. 
21 Id. 
22 Id. 
consists of roughly six injections into the affected site.23 According to Dr. Wehling, 
this treatment is seen as a less intrusive alternative to surgery for many athletes and 
individuals alike. The treatment focuses on problems of inflammation, rather than 
the actual structural make up of the joints.24 Approved for use in Germany around 
2003, Dr. Wehling contends most of his patients are experiencing positive results. 
Dr. Wehling asserts that the treatments success rate is 75 percent and lasts about 4 
years, which is better than some of the procedures currently used in the United 
States to treat similar ailments.25 
While on the surface this procedure is viewed as a miracle cure, opponents of 
the therapy remain skeptical. Dr. Wehling combats this view by citing to a two-year 
study published in the journal of Osteoarthritis and Cartilage.26Dr. Wehling 
concluded “the results confirmed Orthokine/Regenokine therapy provides long 
term relief from pain and joint dysfunction, and in many patients more effectively 
that comparable treatments.”27 The study of 310 individuals reported that following 
the treatment 188 showed improvements with pain and joint functionality.28 Out of 
the remaining 122 individuals, some sought additional treatments but most agreed 
the pain levels were dramatically decreased.29 Many prominent U.S sports stars 
                                                        
23 Id.  
24Nicholas Kulish, Novel Blood Treatment Lures Athletes to Germany, NEW YORK 
TIMES, July 10, 2012, available at http://www.nytimes.com/2012/07/11/sports/athletes-
with-chronic-pain-turn-to-novel-blood-treatment.html?pagewanted=all (last visited April 
20, 2013). 
25 Id. 
26 Id. 
27 Id. 
28 Id.  
29 Id. 
have traveled to see Dr. Wehling in order to undergo such treatment. Some notable 
names are: Kobe Bryant30, Peyton Manning31, and Alex Rodriguez32.  
The Regenokine treatment itself costs about $7,500 U.S dollars.33 Given the 
excessive salary caps of some of these athletes, the cost is merely pennies on the 
dollar. Kobe Bryant is a basketball super-star who plays for the Los Angeles Lakers. 
He is about to turn 34 and has had a long history and knee and joint problems. After 
traveling to Germany to meet Dr. Wehling, Kobe’s recovery is nothing short of 
miraculous.34 Contemplating retirement last season, Kobe seems to have a new 
spark of energy that can only be credited to the Regnokine treatment. Upon his 
return Kobe mentioned his knee feels like that of a 27-year old.35 After speaking so 
highly of the treatment, he was able to convince Alex Rodriguez of the New York 
Yankees to undergo the same procedure.36 “A-rod” sought treatment for knee and 
elbow inflammation and visited Dr. Wehling who has become the foremost specialist 
regarding this procedure37The treatment was done over a period of 5 days, and 
allowed Alex Rodriguez to return to the field shortly after. As this is not a surgery, 
                                                        
30 Jonah Lehrer, Why Did Kobe Go To Germany, GRANTLAND, April 11, 2012, available 
at http://www.grantland.com/story/_/id/7796225/kobe-bryant-dr-chris-renna-regenokine-
knee-treatment (last visited April 23, 2013). 
31 Peyton Manning Underwent Stem Cell Treatment For Neck Injury, HUFFINGTON POST, 
Sept. 20, 2011, available at http://www.huffingtonpost.com/2011/09/19/peyton-
manning-stem-cell-treatment_n_970763.html (last visited April 23, 2013). 
32 Marc Carig, Yankees Slugger Alex Rodriguez Reportedly Goes to Germany for Knee 
Treatment, STAR LEDGER, Dec. 28, 2011, available at 
http://www.nj.com/yankees/index.ssf/2011/12/yankees_slugger_alex_rodriguez_8.html 
(last visited April 24, 2013). 
33 Id.  
34 Id. 
35 Lehrer, supra note 30. 
36 Id. 
37 Carig, supra note 32. 
the recovery time is drastically decreased. Additionally, after a debilitating neck 
injury, NFL quarterback Peyton Manning investigated a similar procedure for 
himself.38 Suffering from a bulging disk, Manning underwent a series of four 
surgeries in attempts to remedy the problem.39 Largely unsuccessful, Manning was 
left to explore other options if he had any hopes of returning to the NFL. He 
stumbled upon a procedure using adult stem cells, specifically his own fat cells, to 
resolve his neck injuries.40 The procedure involved the use of “pluripotent cells” that 
are capable of being programmed into almost anything.41His return to the NFL last 
season came with praise, as well as, reserve. Many were excited that the legendary 
quarterback would once again take the “field of battle.”42 On the other hand, lack of 
support and FDA approval caused many to cast doubt on the choice of treatment by 
Peyton.43 Many believed the treatment was unsupported by scientific evidence, and 
placed Manning in the path of more harm than good. Skeptics request stringent 
clinical trials in order to prove the efficacy of such treatments, but the FDA seems to 
be the biggest hurdle in the way.  
B. Implications For The United States 
The reason these athletes are forced to seek treatment outside of the United 
States is because the Regenokine procedure has not been approved in the United 
States and faces much scrutiny from the FDA. Many doctors in the U.S are wary of 
                                                        
38 Id. 
39 See, Peyton Manning Underwent, supra note 31. 
40 Id. 
41 Id. 
42 Id. 
43 Id.  
practicing adult stem cell therapy and biological medicine, fearing sanctions and 
injunctions from the FDA, as discussed infra in Part III. 
As the current law sits, there are very few, if any, accepted procedures 
involving Regenokine therapy. The category of “biological medicine,” is expanding 
as medical innovations continue to be discovered. Unfortunately, these treatments 
are left to the rich and famous who can cover the costs of traveling to Germany and 
can pay for the therapy out of pocket. A lack of research and proven clinical trials 
has left the FDA skeptical of endorsing such therapies. Although the question 
remains, does the FDA actually have the power to over-see such practices?  Or, is 
this a medical treatment/practice where the FDA has no authority to regulate?  
Without FDA approval, physicians interested in performing these treatments 
are largely limited in their ability. These offices cannot advertise nor promote their 
therapies.44 Most everyday Americans are unwilling to spend money on unproven 
practices. They would favor more conventional methods, although these are not 
necessarily more effective. The lack of FDA approval has effectively outsourced 
these procedures to countries in Europe, like Germany, where regulation is slightly 
less burdensome. This has created a small, but profitable market, open to only those 
willing to pay up and take the risks. Additionally, without the ability to advertise, 
most “average Joes,” are unaware that these alternatives exist. The center of 
Regenokine Therapy is located in Dusseldorf, Germany as mentioned above.45While 
                                                        
44 Kulish, supra note 24. 
45 This demonstrates the method in which one would obtain an appointment with Dr. 
Wehling and learn about his practice. Wehling-Hartman, located in Dusseldorf, Germany, 
available at http://www.wehling-hartmann.de/en/wir-ueber-uns/aerzteteam/ (last visited 
April 24, 2013). 
advertised scarcely on the Internet, most everyday Americans do not have the 
means of acquiring such luxuries. Those in a position to seek treatment, might be 
dissuaded due the “lack of proof,” or existence of substantial clinical trials.46 The 
Supreme Court of the United States confronted this issue, although it remains 
largely ambiguous and undecided. The issue is one of interpretation and framing, 
depending on the reading of various FDA regulations. It is clear that the government 
has an interest in preventing harm and spread of disease through untested 
procedure, but the obstacles do not need to be so burdensome. While the FDA and 
Surgeon General have an interest in regulations necessary to “prevent the 
introduction, transmission, or spread of communicable diseases from foreign 
countries into the United States, or from state to state,47this is unjustified in 
treatments where an individual is introducing his own biologic material into his 
own body. 
By addressing and analyzing the current law, and pending litigation, we can 
predict future outcomes and the direction this new age treatment is heading. For the 
remainder of this paper I plan on discussing the pros and cons of our government’s 
approach, along with the slippery slope of consequences that could arise, if action is 
not taken soon. 
III. FDA Regulation of Adult Stem Cell Therapies 
A. The Statue and FDA Regulation 
In 1938, Congress passed the Food, Drug, and Cosmetic Act, (“FDCA”). It 
provided the FDA with the power to, “regulate the introduction or delivery for 
                                                        
46 Id. 
47 42 U.S.C. §264A. 
introduction into interstate commerce of any food, drug, device, or cosmetic, that is 
adulterated or misbranded,” in order to protect the public health.48 As this was 
designed specifically for consumer goods, medical practices fall outside the scope of 
regulation. “The bill is not intended as a medical practices act, and will not interfere 
with the practice of the healing art by chiropractors and others in the States where 
they are licensed by law to engage in such practice.”49 The intent appears to be clear, 
in the sense that Congress would continue to allow physicians to treat patients in 
accordance with state laws, and practices they deemed appropriate.50 Fearing 
unintended consequences, the act was modified to ban the shipment of interstate 
drugs not deemed safe, unless a New Drug Application “NDA” was filed.51This 
safeguard required manufacturers to disclose the drugs components, composition, 
manufacturing process, intended use, and additionally establish that the drug was in 
fact safe for its intended use.52 Additional Amendments passed in 1962 imposed 
liability on pharmaceutical companies for mislabeling or inaccurately advertising 
the drugs they manufactured. On the surface, it appears the Congress was still 
reluctant to govern the practice of medicine, although these measures imposed 
additional requirements on developers of drugs, not prescribers. The intent of 
Congress for physicians to be free from FDA involvement did not last long. The 
potential for intersection becomes more obvious when we consider the definition of 
“drug,” as defined by the FDCA in §321(g).  
                                                        
48 21 U.S.C §331(a). 
49 Gonzalez v. Oregon, 546 U.S. 243, 258 (2006). 
50 Id.  
51 21 U.S.C §335(b). 
52 Id.  
The FDA considers drug as “articles intended for use in the diagnosis, cure, 
mitigation, treatment, or prevention of disease,”53or “any substance intended to 
affect the structure or any function of the body.”54 To determine what constitutes an 
intended use, the FDA focuses on the intent of the individual responsible for labeling 
such drugs.55 Like most governmental agencies, the FDA is given a lot of deference 
and typically interprets their own definitions along with intended uses to determine 
whether a substance qualifies as a drug.56 This has proved to be troubling and often 
causes difficulties for those wishing to challenge FDA interpretation.57 This proves 
to be increasingly difficult when faced with new age products developed as 
biological cures or medicines.  
Around 1944, Congress confronted this issue and passed the Public Health 
Service Act, (“PHSA”).58Recognizing a potential different between biologics and 
drugs, this act imposed separate regulatory requirements. The FDA grants licensing 
for biologics proven to be “safe, pure, and potent.”59 It is important to keep in mind 
these actions were taken prior to the discovery and implementation of stem cell 
therapies. Rather than being considered NDA’s the biologic material would have to 
apply for Biologic License Applications, (“BLA”). This led to confusion in 
determining exactly which substances were considered drugs, and which were 
                                                        
53 21 U.S.C §321(g)(1)(b) (2009). 
54 21 U.S.C. §321 (g)(1)C (2009). 
55 21 CFR §210.128 (2011). 
56 Id. 
57 Id. 
58 42 U.S.C. §262 (2010). 
59 42 U.S.C §262 (a)2(c)(i)(I) (2010). 
biologics. After much advancement in the medical field in the 1990’s the FDA once 
again decided to take action. 
With the advancement of biological medicine the FDA needed to find a way to 
regulate human cells, tissues, and other genetically comprised products. In 1997, the 
FDA enacted C.F.R §1271. Human cell and tissue-based products, (“HCT/P”), would 
come into the scope of regulation in 2001.60 Recognizing that certain substances 
have inherently more risks than others, the FDA developed a three-tier system to 
address these HCT/P’s.61  
The first category of substances required no oversight by the FDA if two 
criteria were met. The manufacturer of the HCT/P’s could not do more than 
(1)“minimally manipulate” the biologic substance, and (2) the use must be 
“homologous,” effectively performing the same basic function in the recipient as the 
donor.62 While this provided some guidance, the term “minimally manipulated” fails 
to be defined within the regulation. 
The second category of biologics requires minimal oversight by the FDA. 
Under §361 of the PSHA these products included cells, tissues, or other products 
posing a slightly higher risk.63 Again the FDA laid out certain criteria that would 
qualify for minimal over-sight.64 In addition to the two factors mentioned above, the 
FDA requires the manufactures to refrain from the combination of cells or tissues 
with other articles, and used for autologous use, in a first or second degree blood 
                                                        
60 21 C.F.R. 1271.10(a). 
61 Id.  
62 21 C.F.R. §1271.3(d). 
63 Id. 
64 Id. 
relative, or for reproductive use.65 While the FDA recognized these substances as 
posing a slightly higher risk, the do not require NDA, BLA, or are considered to be 
Investigative New Drugs, (“IND”).66 The FDA mentions that certain products when 
combined with other substances may induce a therapeutic effect, thus requiring 
stricter regulation. Therefore the FDA created a third category of biologics. 
The final category falls under §351 of the PHSA.67The FDA considered these 
substances to be more than minimally manipulated, and intended for “non-
homologous” use.68 This includes products manipulated through gene or tissue 
culture and according have no biological precedent for such use.69 Accordingly, 
products in these categories are required to undergo pre-market reviews and 
applications for a BLA.70Additionally, those involved in the manufacture of such 
products must follow current Good Manufacturing Practices.71 
Following codification of the regulations, much confusion ensued. Physicians 
and manufactures were unclear about which tier their products fell into and what 
level of regulation was required. In 2006, the FDA attempted to clarify their position 
by stating, “HTC/P’s are articles consisting or containing human cells or tissues that 
are intended for implantation, transplantation, infusion, or transfer to a human 
recipient.72 While this clarification proved to be helpful, it made no more distinction 
between substances taken from one individual and implanted into another, as 
                                                        
65 Id. 
66 21 C.F.R. §207, §807 (2012). 
67 42 U.S.C §262. 
68 Id. 
69 21 C.F.R §1271.20. 
70 42 U.S.C. §262(a). 
71 21 C.F.R. §207.3(a)(8). 
72 21 C.F.R. §1271.3. 
opposed to procedures where the substance is taken and then implanted back into 
the same individual.  
The FDA made additional attempts to clarify their regulations in 21 C.F.R 
§1271.3(4), where they define minimal manipulation for structural tissue as 
“processing that does not alter the original relevant characteristics of the tissue 
relating to the ability for reconstruction, replacement, or repair”.73 For cells, 
minimal manipulation is considered “processing that does not alter the relevant 
biological characteristics of the cells.”74Additionally the FDA defined homologous 
use in 21 C.F.R §1271.3(c) as, “the repair, reconstruction, replacement, or 
supplementation of a recipients cells or tissues with an HCT/P that performs the 
same basic function in the recipient as the donor.”75 According to the FDA the 
substance would need to be submitted as a BLA. Again this makes no mention or 
distinction if the recipient and donor are the same individual. While the biologic 
material performs the same basic function, the FDA does not address instances 
where the function is simply heightened or strengthened but at its core the function 
remains the same. As research and treatments continued to be discovered, other 
physician began to develop procedures using these substances. While the current 
state of the law is up for debate, the Regenexx case provides insight into the mind of 
the government and FDA. 
B. Regenerative Sciences, Inc v. U.S. Food and Drug Administration 
                                                        
73 Id. 
74 21 C.F.R. §1271.3(4). 
75 21 C.F.R §1271.3(c). 
Regenerative Sciences, LLC owned and operated a clinic in Broomfield, 
Colorado. The procedure known as “Regenexx,” was viewed as an alternative to 
orthopedic surgery.76 The procedure involved removing bone marrow samples from 
the patient, along with blood. The samples were then cultivated and induced to 
grow additional cells.77 This solution was then re-injected back into the patient 
where the natural conditions of the body continued to encourage the growth, 
healing, and regeneration of cells.78After viewing this procedure, the FDA 
considered it to be a drug, inside the scope of regulation, thereby mandating FDA 
approval in order to market.79 Regenerative Sciences in turn, challenged the findings 
of the FDA and brought suit claiming this practice falls outside the scope of the 
FDA’s jurisdiction.80In the following section I plan to break down the reasoning of 
the FDA, and discuss why the interpretation should favor the Regenexx Procedure, 
rather than discourage it. Additionally, I wish to contrast the Regenokine therapy 
mentioned above, from that of Regenexx. While courts typically give deference to 
regulatory agencies, it may nonetheless be misplaced and have unintended 
consequences 
                                                        
76 Letter from Mary A. Malarkey, Dir. Of Compliance and Biologics Quality, U.S. Food 
and Drug Admin., to Christopher J. Centeno, M.D., Med. Dir., Regenerative Sci., Inc. 
(July 25, 2008) available at 
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformatio
n/ComplianceActivities/Enforcement/UntitledLetters/ucm091991.htm (last visited April 
18, 2013). 
77 Regenexx, Procedure Explained, available at http://www.regenexx.com/the-regenexx-
procedure-explained (last visited April 15, 2013). 
78 Id.  
79 21 U.S.C. 321(g)(1) (2006), 42 U.S.C §262. 
80 U.S v. Regenerative Sciences, LLC, 878 F. Supp. 2d 248 (2012). 
The main issue in the Regenexx case involved the Regenexx procedure and 
whether it constitutes a drug or biologic within the scope of FDA regulation, or on 
the other hand, a medical practice as intended by Congress to be out of the reach of 
the FDA. As mentioned above, the Regenexx procedure was a treatment using 
“bone-marrow derived stem-cells” to treat various joint injuries.81 After reviewing 
these procedures, the FDA concluded Regenexx was in violation of 21 C.F.R. §1271 
and sought an injunction.82 Additionally, the FDA posted a letter on the Regenexx 
website stating their procedures were not approved and may have been 
unlawful.83The FDA concluded Regenerative Sciences Inc., was a drug manufacture 
and in violation of federal regulations.84 Accordingly, Regenexx filed a counter-claim 
challenging the findings of the FDA. The appeal was heard in 2012, and once again 
left the issue largely undecided.  
Located in Colorado, Regenexx sought to defeat the FDA by citing to the 
pertinent law in their state85. The FDA conceded that Regenexx is in fact engaged in 
the practice of medicine, but rather attacked the Colorado law for being too vague. 
The FDA rested their argument on the contention that the procedure is a drug as 
defined and falls into the scope of regulation.86 Additionally, the FDA qualifies the 
Regenexx procedure as a prescription drug since, “due to it’s toxicity or other 
potentially harmful effect, or the method of its use, is not safe for use except under 
                                                        
81 Id. 
82 Regenerative Sciences, Inc., v. U.S. Food and Drug Admin. 2010 WL 1258010. 
83 Id. at 253. 
84 Id.  
85 COLO Rev. Stat. Ann. §12-36-106(1) (2012). 
86 Id. 
the supervision of a practitioner licensed by law to administer such drug.87 
Furthermore, the procedure according to the FDA is a biologic under the definition, 
as a substance may be both a biologic and a drug.88 While the focus largely remained 
with the interpretation of the statutory language, the FDA additionally claims the 
use by Regenexx was more than minimal manipulation as provided in the 
regulations. The procedure involves a physician drawing a bone marrow sample 
from a patient through a syringe.89Small amounts of the patient’s blood are also 
drawn, and sent to the Regenexx laboratory. Here, the mesenchymal stem cells, 
(MSC), are isolated from the bone marrow and then grown to a greater number.90 
Thus far, this seems to be only minimal manipulation. The cells are performing the 
same task as they do in the donor; the procedure simply cultivates a greater number 
of individual cells. The cells are then placed into a flask, kept in a warm 
environment, and mixed with the patient’s own blood and a nutrient solution.91 This 
is perhaps where the FDA’s concerns begin. This nutrient solution seems to be a 
cause for concern as it manipulates the way in which these individual cells function 
and grow. The FDA assumes that this goes beyond minimal manipulation92, but their 
conclusion is without merit. The procedure also calls for a substance to separate the 
cells to be used, from the flask they are stored in.93Again the FDA fails to recognize 
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this as minimal manipulation. In response, Regenexx filed various counter-claims 
and disputed the findings of the FDA, but were ultimately unsuccessful.94 
The court acknowledges that the FDA is entitled to deference based on their 
expertise in evaluating scientific data.95 Based on this language and deference, it was 
concluded that Regenexx was a drug and biologic manufacturer subject to FDA 
regulation.96 Additionally, their product was subject to the highest tier of scrutiny 
requiring filing for IND, NDA, and BLA’s, none of which Regenexx had done. The 
addition of more than minimal manipulation took the procedure outside of the 
scope of §351 substances.97Accordingly, the court granted the FDA’s motion for 
summary judgment, dismissed the counterclaims of Regenexx, and instituted a 
permanent injunction98. The issue is once again on appeal for the D.C Circuit. 
C. Regenokine Therapy Different From The Regenexx Procedure 
The Regenokine therapy performed by Dr. Wehling is fundamentally similar 
to the Regenexx treatment, although less intrusive and cumbersome. The procedure 
does not call for the use of bone marrow, only about 2 fluid ounces of blood.99 The 
blood is then placed into an incubator where under this higher temperature its 
ability to relieve inflammation increases about one hundred times the normal 
amount.100 After the blood develops a “fever,” it is placed into a centrifuge and spun, 
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until a viscous substance is formed.101 The “fever” involves a process where the 
temperature of the blood is raised to elicit a natural and biological response, as if a 
fever had occurred in the body of the patient. This substance is then drawn with a 
syringe and injected back into the patient.102 It does not appear that any additional 
drugs, minerals, or solutions are mixed with the patient’s blood. Aside from raising 
the temperature, and causing the cells to separate in the centrifuge, no additional 
alterations are necessary.103 This clearly falls within the scope of minimal 
manipulation. Since no harmful materials are added, the blood solution should not 
be considered a drug. It is no different than an individual getting a blood 
transfusion, a medical practice that the FDA does not regulate. Furthermore, the 
blood is placed back into the patient, so the concern about the spread of infectious 
disease is drastically mitigated. Finally, the newly injected cells perform that same 
basic function as they did, prior to being removed. The only difference is in their 
strength and number. Just like your immune system thrives off of vitamin C, this 
therapy simply gives the body a boost of healing power. Nonetheless, the FDA 
remains firm in their belief that these therapies are actually drugs and since they 
involve biologic material, they are subject to the highest level of regulation. As 
mentioned, the term “minimally manipulated” remains largely undefined, but the 
FDA refuses to change their position, which makes practicing these new age 
treatments virtually impossible. 
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IV. Implications For Future Development of Adult Stem Cell Therapies 
In The United States. 
The FDA consistently refuses to adopt such practices. They consider this to 
be a drug and biologic within the scope of regulation as mentioned by the Regenexx 
case. Although the case is up for appeal, physicians and scientists remain skeptical of 
adopting these treatments in the United States. This puts our nation at a great 
disadvantage compared to other countries where these therapies are not only being 
performed, but perfected on a daily basis. As mentioned above, this minimal 
development has caused those who can afford it, to travel abroad. The FDA is 
effectively outsourcing our healthcare system to countries with less stringent 
requirements. Although the long-term effects of these regenerative procedures have 
not been conclusively studied, the overwhelming success rate gives reason to 
remain optimistic.104Unlike purchasing prescription drugs, these procedures 
require individual visitation with a qualified physician, who will then perform the 
procedure. One cannot simply go into a pharmacy and purchase these cells. While 
Regenexx and Dr. Wehling maybe the people carrying out such treatments, it is a 
stretch to considered them manufactures of drugs, as the FDA contends. If anyone is 
to blame, it is the individual patients themselves. After all, the final solution initially 
comes from the patient, therefore holding him/her as the true manufacture. While 
strictly speaking the statutory language may allow the FDA to control these types of 
practices, in today’s day and age this does more harm than good. The hindrance of 
progress and medical development directly contradicts the mission of the FDA. In 
                                                        
104 Regenexx, Procedure Explained, available at http://www.regenexx.com/the-
regenexx-procedure-explained (last visited April 15, 2013). 
attempts to protect, they actually destroy any hopes of developing life-changing 
cures. 
The strict yet ambiguous requirements of the FDA deter most U.S. companies, 
physicians, and scientists from engaging in potentially life changing procedures. 
This a phenomenon known as, “Stem cell tourism.105” As mentioned, this has 
become common among various athletes and prominent individuals, but more 
difficult for the “common man.” Even the late Pope John Paul II has endorsed this 
Regenokine procedure, outside of the United Stated away from the reach of the 
FDA.106 Those willing to pay out of pocket can take advantage of these advanced 
procedures, while others are left to more intrusive surgeries. Physicians are faced 
with a “double-edged sword.” On one hand they can attempt to abide by the FDA 
requirements. This is troublesome since the FDA requirements regarding biologics 
remain unclear. Physicians would need to apply for NDA, IND, and BLA’s. This 
process would increase costs, delay progress, and impede access.107 While the 
therapy overseas costs about $7,500 dollars, these additional steps could potentially 
sky rocket the price in the United States. Insurance companies would be unwilling to 
cover risky or unproven treatments, and individual would again be forced to bear 
the costs on their own.  These FDA hurdles delay access to the public. While many 
with chronic conditions are unable to travel outside of the United States, or afford 
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expensive treatments, the FDA is taking no measures to further the availability of 
comparable treatments. On the other hand, those truly dedicated to the practice of 
biological and genetic medicine can follow the path of Regenexx. If a valid and 
successful treatment is discovered, they could attempt to remain under the radar 
and not advertise their procedure. This appears to be what the FDA is encouraging, 
since the formal process will most likely lead to an injunction or disproof of the 
newly discovered procedures.  
Conversely, if the FDA decides to be “hands-off,” many unproven or 
hazardous treatments could come into the market. Physicians would be altering all 
different types of genetic material in hopes of finding cures to debilitating diseases, 
which in turn could actually cause more problems. Opponents of genetic therapies 
believe this outcome would turn the medical community into the “Wild Wild West,” 
of biological medicine. This seems to be stretch considering most physicians 
genuinely care about treating their patients. These regulations should be left to the 
states. Rather than travel to Germany, individuals could simply cross state lines if 
they wish to undergo certain procedures possibly un-adopted by their home state. I 
am by no means suggesting this new age medicine should be free of all regulation. 
Simply put, the current state of the law is a cause for concern. Regulation of genetic 
material is a necessary in the medical community, but as of right now the FDA has 
over-reached and gone too far. In order to catch up, create access, and endorse 
progress, the FDA should tone down the way in which they define, regulate, and 
control these practices. While it remains uncertain about how the Regenexx case 
will play out in the future, and what effect it will have on development, action should 
be taken sooner than later. The point of health care reform is to provide equal 
access to all, although currently the rich and famous have many more access than 
the everyday man.  
 
 Conclusion 
The unwillingness of the FDA to adopt clear “bright-line” rules and ease the 
tedious requirements of getting approval has severely diminished the abilities of 
physicians in the United States to engage in these break through procedures. 
Concerns about “stem-cell tourism” continue to grow, as the majority of the public 
has no alternative, but to seek treatment outside of this country. The FDA 
requirements as a whole continues to increase costs, cause delays, and impede 
access for those who cannot afford the luxury of traveling abroad. These autologous 
stem cell treatments are far less controversial than their embryonic counterparts, 
since the cells are drawn and later re-injected into the patient’s own body. Critics 
have called the FDA’s position “close-minded.” Patients should have the ability to 
weigh the risks and benefits for themselves, provided that they have access to 
information surrounding these treatments. Thus far, the FDA has limited the 
procedure itself, as well as the transmittal of information surrounding these 
treatments. 
The FDA does not allow the commercialization of these treatments until 
proper approval is granted. The hurdles they put in place have a counter effect as 
they discourage physicians from engaging in said practices, for fear of injunctions 
and even worse, termination of one’s medical license. In today’s society, technology 
is advancing each and every day, however access to this technology has slowed to a 
crawl due to the actions of the FDA. The potential of these adult stem cell therapies 
is tremendous, but unfortunately the United States continues to remain leagues 
behind due to the unfortunate position taken by the FDA. The current state of the 
law remains unclear, and it does not appear that the water will be cleared up 
anytime soon. Those brave physicians willing to embrace these new cutting edge 
treatments must constantly live in fear, as the FDA could “shut them down” at any 
minute. Without the ability to advance our healthcare system, we will never be able 
take the next step and actually use these adult stem cells to their full potential.    
